NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
TrumpCrisisFebruaryTariffsSafetyRefundCourtUkraineNewsDigestTimelineIssueAdditionalAnnounceSupremeChinaYearsBillionZmirCampaignIncreasedDailyMondayDays
TrumpCrisisFebruaryTariffsSafetyRefundCourtUkraineNewsDigestTimelineIssueAdditionalAnnounceSupremeChinaYearsBillionZmirCampaignIncreasedDailyMondayDays
All Articles
STAT+: Gilead to buy Arcellx in nearly $8B deal
STAT News
Published about 1 hour ago

STAT+: Gilead to buy Arcellx in nearly $8B deal

STAT News · Feb 23, 2026 · Collected from RSS

Summary

Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.

Full Article

The two companies were already partnered on a multiple myeloma CAR-T treatment Justin Sullivan/Getty Images By Adam FeuersteinFeb. 23, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Gilead Sciences said Monday it is acquiring Arcellx in a deal worth $7.8 billion, merging two biotech companies already co-developing a CAR-T therapy for multiple myeloma. The transaction values Arcellx at $115 per share, or a 79% premium to the stock’s Friday close. Arcellx shareholders will also be eligible for an additional payment equal to $5 per share, based on achieving a future sales target. The centerpiece of the deal is an experimental CAR-T therapy called anito-cel that was initially developed by Arcellx. Since 2023, the therapy has been co-developed by Kite Pharma, Gilead’s cell therapy division, as part of a collaboration and co-marketing agreement. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.


Share this story

Read Original at STAT News

Related Articles

STAT Newsabout 2 hours ago
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study

Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study.

STAT Newsabout 2 hours ago
Women’s heart attack risk rises even if arteries aren’t as clogged as men’s

The smaller arteries of women means a little plaque can be more dangerous than it is for men.

STAT Newsabout 3 hours ago
STAT+: Pharma lobbyists focus on a surprising new target: the FDA

Lobbyists told STAT they believe the odds of approval go up if a decision can be spun as a win for the Trump administration.

STAT Newsabout 3 hours ago
STAT+: Lobbying firms with close ties to Trump draw pharma industry clients

Business is booming for Trump-connected lobbying firms as pharma giants see new opportunity to influence the FDA.

STAT Newsabout 3 hours ago
Opinion: No one in health care should be called a ‘provider’

The word “provider” in health care turns the relationship between patient and physician into a commercial transaction, argues the American College of Physicians.

STAT Newsabout 3 hours ago
STAT+: Health care reform might be a focus in midterms. For Congress, pursuing it will be an uphill climb

Lawmakers will likely have a lot to say about health care this year. Paradoxically, they probably won't accomplish much on the subject.